论文部分内容阅读
目的研究131I－LPD选择性内辐射治疗原发性肝癌的吸收剂量及其疗效。方法对8例经手术证实不能切除的肝癌患者经肝动脉反复灌注131I－LPD计算癌组织的吸收剂量，观察其疗效。结果8例平均接受了25次内辐射治疗，放射性活废为（529±127）MBq.131主要聚集在肝癌病灶，癌肝放射性计数比值（T／NT）为2．50～8．50（SD5．60±1．78）。癌组织接受的内辐射吸收剂量为（1792±774）cGY。8例中有5例AFP＞500μg／L，，治疗后转为正常。其中4例因癌肿缩小得以再切除。8例的3年生存率为74％，5年生存率为56％。结论131I－LPD经肝动脉灌注是较理想的内辐射治疗肝癌的方法。
Objective To study the absorbed dose of 131I-LPD selective internal radiation therapy for primary liver cancer and its efficacy. Methods Eighteen patients with hepatocellular carcinoma who had been proved to be unresectable by surgery were treated with hepatic artery 131I-LPD. The absorbed dose of cancer tissue was calculated and the curative effect was observed. Results Eight patients received an average of 25 internal radiation treatments. The radioactive waste was (529±127) MBq.131 mainly accumulated in liver cancer lesions, and the tumor radioactivity count ratio (T/NT) was 2.50 to 8.50 (SD5 .60±1.78). The amount of internal radiation absorbed by the cancer tissue was (1792±774) cGY. Five of 8 patients had an AFP of >500 μg/L, which became normal after treatment. Of these, 4 were re-excised due to shrinking cancer. The 3-year survival rate was 74% in 8 patients and the 5-year survival rate was 56%. Conclusion 131I-LPD perfusion through hepatic artery is an ideal method to treat liver cancer with internal radiation.